Drug Reverses Liver Scarring in Mouse Study
Pegozafermin, an FGF21 analog already in phase 3 trials, reduced fibrosis and showed signs of regressing cirrhosis in mice.
Updated on Nov. 7, 2026 in Weight Loss
Preclinical findings presented at The Liver Meeting 2026 show that pegozafermin reversed fibrosis and showed signs of regressing established cirrhosis in mice. Treatment that began after animals reached advanced fibrosis or cirrhosis also prevented hepatocellular carcinoma in the model.
Why it matters
Liver scarring and cirrhosis can progress to liver failure and cancer, and the study suggests a drug could potentially address established disease rather than only early stages. Because pegozafermin is already in phase 3 trials for other uses, the findings add to an existing body of clinical development.
The findings come from a diet-based mouse model in which treatment began only after animals reached advanced F3 fibrosis or F4 cirrhosis, with liver collagen falling below pretreatment levels. Hard end points including cirrhosis and hepatocellular carcinoma were measured, but the researchers note that confirming cancer prevention will require large, long-term studies.
The players
Zaur Abilov
Researcher affiliated with Beth Israel Deaconess Medical Center who is involved in the pegozafermin mouse study.
Beth Israel Deaconess Medical Center
Teaching hospital of Harvard Medical School in Boston that is affiliated with the researcher presenting the findings.
The details
Pegozafermin is a long-acting FGF21 analog. In mice treated at the F3 stage, the drug prevented progression to cirrhosis, while in animals with established cirrhosis, tissue analysis showed reversal of scarring.
Timeline
2026: Preclinical findings presented at The Liver Meeting 2026.
Health Landscape
The study extends the clinical development of FGF21 analogs, a drug class now advancing through late-stage trials for liver disease. Its reported effects on established cirrhosis, rather than early fibrosis alone, mark a step beyond earlier preclinical work in this area.
For people with fatty liver disease, these findings are preclinical and do not change current treatment or monitoring. Readers with liver concerns should continue working with their clinicians on established care while the drug's development proceeds.
The takeaway
Reversal of cirrhosis in mice is a promising signal, but it is far from proof of benefit in people. Readers should watch for clinical trial results before drawing conclusions about liver disease treatment.
Further reading
For related coverage of metabolic treatments, see Weight Loss.
Source note: This article includes information reported by Ajmc.
